MALVERN, Pa. and SAN DIEGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and ...
-First clinical evaluation of BB-025, designed to rapidly and specifically reverse BB-031 activity, advancing Basking's goal to redefine thrombosis treatment- RESEARCH TRIANGLE, N.C., Nov. 12, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback